Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20804232 | 0.83 | FDPS (0.31) | GABRR1 | |
| SCHEMBL10879775 | 0.80 | GABRR1 (0.46) | CYP1A2CYP3A4CYP2C9HIF1AGABRR1 | |
| SCHEMBL12157045 | 0.79 | ALDH1A1 (0.33) | ALDH1A1TDP1 | |
| SCHEMBL19491568 | 0.79 | ALDH1A1 (0.33) | ALDH1A1TDP1 | |
| SCHEMBL1578753 | 0.78 | TDP1 (0.33) | CYP1A2CYP3A4CYP2C9HIF1ATDP1 | |
| SCHEMBL14215959 | 0.75 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL21302039 | 0.75 | — | — | |
| SCHEMBL19364153 | 0.75 | CYP1A2 (0.33) | CYP1A2CYP3A4CYP2C9HIF1A | |
| SCHEMBL14459291 | 0.75 | SMN1; SMN2 (0.37) | CYP1A2CYP3A4CYP2C9HIF1AALDH1A1 | |
| SCHEMBL26385278 | 0.75 | SMN1; SMN2 (0.37) | CYP1A2CYP3A4CYP2C9HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2017092759-A1 | GEPHYRIN BINDING PEPTIDES AND USES THEREOF | UNIVERSITY OF COPENHAGEN (DK) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | DHFR, TYMS, TYMP | CYP1A2 77/4885CYP3A4 39/4885CYP2C9 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.